These findings indicate that this allele-specific siRNA effectively reverses key ALS-related cellular deficits in motor neurons, representing a promising candidate for targeted therapy in patients carrying the TDP-43 G376D mutation. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.